NexGel Inc (NXGL)
NASDAQ:NXGL
Top Page
NexGel Inc
(NASDAQ:NXGL)
Select Model
Select Model
Rating:51Neutral
Price Target:
$1.00
▼(-39.02% Downside)
Action:ReiteratedDate:01/08/26
The score is driven primarily by still-weak financial fundamentals (ongoing losses and negative free cash flow) despite improving margins and prior revenue scaling. Technicals are mixed with the stock below key longer-term moving averages. Guidance and partnerships support a better near-term outlook, but flat recent revenue and partnership/logistics uncertainties temper confidence, and valuation metrics provide limited support due to negative earnings.
Positive Factors
Improved Gross Margins
Sustained gross-margin improvement to 42.4% reflects better product mix and manufacturing execution, increasing operating leverage potential. Higher margins provide durable cushion for profitability as revenue scales, reducing breakeven revenue and supporting longer-term cash flow improvements even if growth moderates.
Negative Factors
Negative Operating Cash Flow
Persistent negative operating and free cash flow (~-$2.5M TTM) forces reliance on external financing, increasing dilution or debt risk. Until core operations generate positive cash, growth initiatives and marketing push require funding, constraining strategic flexibility and raising sustainability concerns over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Gross Margins
Sustained gross-margin improvement to 42.4% reflects better product mix and manufacturing execution, increasing operating leverage potential. Higher margins provide durable cushion for profitability as revenue scales, reducing breakeven revenue and supporting longer-term cash flow improvements even if growth moderates.
Read all positive factors
NexGel Inc (NXGL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.08M
Dividend YieldN/A
Average Volume (3M)50.95K
Price to Earnings (P/E)―
Beta (1Y)0.85
Revenue Growth73.38%
EPS Growth34.87%
CountryUS
Employees19
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.08
Shares Outstanding8,143,133
10 Day Avg. Volume60,354
30 Day Avg. Volume50,949
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)5.05
Price to Sales (P/S)3.34
P/FCF Ratio-6.74
Enterprise Value/Market Cap1.31
Enterprise Value/Revenue0.80
Enterprise Value/Gross Profit2.08
Enterprise Value/Ebitda-4.15
Forecast
1Y Price Target
$2.00Price Target Upside21.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.06
Revenue Forecast (FY)$16.88M
NexGel Inc Business Overview & Revenue Model
Company Description
NexGel Inc (NXGL) is a specialized healthcare company that focuses on the development and commercialization of innovative hydrogels and other products primarily for the medical and personal care markets. The company operates in the healthcare sect...
How the Company Makes Money
NexGel generates revenue through the sale of its proprietary hydrogel products to healthcare providers, distributors, and retail outlets. The company has established key partnerships with healthcare institutions and manufacturers that facilitate t...
NexGel Inc Earnings Call Summary
Earnings Call Date:Nov 11, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Mar 31, 2026
Earnings Call Sentiment Neutral
The call presented a balanced view of the company's performance, with significant highlights in improved gross profit margins, strategic partnerships, and product expansions. However, revenue growth was flat, and logistical delays and partnership uncertainties posed challenges.Positive Updates
Improved Gross Profit Margins
Gross profit margin for Q3 2025 was 42.4%, an increase from 39.3% in Q3 2024.
Negative Updates
Flat Revenue Growth
Q3 2025 revenue was flat year-over-year at $2.9 million, with contract manufacturing and branded product revenue remaining stable.
Read all updates
Q3-2025 Updates
Positive
Negative
Improved Gross Profit Margins
Gross profit margin for Q3 2025 was 42.4%, an increase from 39.3% in Q3 2024.
Read all positive updates
Company Guidance
During the call, NEXGEL provided guidance for the remainder of 2025, indicating that they expect fourth-quarter revenues to increase sequentially and potentially set a record for the company. They project full-year revenues to range between $12 and $12.5 million, with the higher end being contingent on a strong holiday season for consumer branded products. The company also highlighted its focus on narrowing its adjusted EBITDA loss, which was reduced to $354,000 in the third quarter, with expectations to approach breakeven in the fourth quarter. The company is leveraging its partnerships and new product launches to drive growth, including their collaboration with iRhythm and the expanding relationship with Stada, supported by $1 million in non-dilutive financing to aid upcoming launches and marketing.NexGel Inc Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
56
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.66M | 8.69M | 4.09M | 2.05M | 1.55M | 674.00K |
| Gross Profit | 4.47M | 2.75M | 374.00K | 256.00K | 8.00K | -291.00K |
| EBITDA | -2.23M | -2.90M | -2.73M | -3.11M | -2.17M | -2.20M |
| Net Income | -2.88M | -3.28M | -3.16M | -4.75M | -4.31M | -2.26M |
Balance Sheet | ||||||
| Total Assets | 11.62M | 10.98M | 9.96M | 10.36M | 16.98M | 2.26M |
| Cash, Cash Equivalents and Short-Term Investments | 938.00K | 1.81M | 2.70M | 6.61M | 13.35M | 32.00K |
| Total Debt | 3.19M | 2.83M | 2.80M | 2.08M | 4.26M | 1.28M |
| Total Liabilities | 6.04M | 4.90M | 4.79M | 2.72M | 4.90M | 2.19M |
| Stockholders Equity | 5.19M | 5.75M | 4.70M | 7.64M | 12.09M | 71.00K |
Cash Flow | ||||||
| Free Cash Flow | -2.55M | -4.31M | -3.93M | -3.09M | -3.02M | -2.11M |
| Operating Cash Flow | -2.45M | -3.87M | -3.24M | -2.99M | -2.75M | -1.80M |
| Investing Cash Flow | -91.00K | -775.00K | 4.46M | -5.59M | -269.00K | -312.00K |
| Financing Cash Flow | 3.34M | 3.75M | 379.00K | -3.66M | 16.34M | 1.88M |
NexGel Inc Technical Analysis
Negative
1.64
Price Trends
1.17
Negative
1.47
Negative
1.97
Negative
Market Momentum
-0.15
Positive
30.25
Neutral
12.36
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NXGL, the sentiment is Negative. The current price of 1.64 is above the 20-day moving average (MA) of 0.87, above the 50-day MA of 1.17, and below the 200-day MA of 1.97, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 30.25 is Neutral, neither overbought nor oversold. The STOCH value of 12.36 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NXGL.
NexGel Inc Risk Analysis
NexGel Inc disclosed 30 risk factors in its most recent earnings report. NexGel Inc reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NexGel Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $7.08M | -7.45 | -55.33% | ― | 73.38% | 34.87% | |
46 Neutral | $155.47M | -5.36 | -178.57% | ― | 30.55% | -340.19% | |
45 Neutral | $32.35M | -4.53 | -60.56% | ― | 13.67% | -37.01% | |
43 Neutral | $20.06M | -1.84 | -8.13% | ― | -0.95% | 58.17% | |
42 Neutral | $20.92M | -8.10 | -164.78% | ― | 0.59% | -39.76% | |
41 Neutral | $28.70M | ― | -764.17% | ― | 63.53% | 12.49% |
* Healthcare Sector Average
NXGL
NexGel Inc
0.66
-2.32
-77.85%
RVP
Retractable Technologies
0.67
-0.03
-4.69%
MLSS
Milestone Scientific
0.27
-0.67
-71.46%
POCI
Precision Optics Corporation
4.19
0.04
0.96%
SMTI
Sanara MedTech
16.96
-13.91
-45.06%
FEMY
Femasys
0.48
-0.77
-61.44%
NexGel Inc Corporate Events
Executive/Board Changes
NexGel director and compensation chair Nachum Stein resigns
Neutral
Jan 30, 2026
On January 29, 2026, NexGel Inc. announced that board member Nachum Stein, who serves as chairperson of the board’s Compensation Committee, notified the company of his intention to resign from the Board of Directors effective February 2, 202...
Executive/Board Changes
NexGel Names Adam Drapczuk Interim Chief Financial Officer
Neutral
Jan 7, 2026
Effective January 1, 2026, NexGel, Inc. appointed veteran finance executive Adam E. Drapczuk III as interim chief financial officer, as well as principal financial and accounting officer, succeeding Joseph F. McGuire, whose employment ended on Dec...
Business Operations and StrategyProduct-Related Announcements
NexGel Inc Announces Spin-Off of Drug Delivery Unit
Positive
Dec 11, 2025
On December 11, 2025, NEXGEL, Inc. announced the spin-off of its drug delivery program into a new entity, NexGelRx, which will focus on developing prescription drug delivery solutions using NEXGEL’s proprietary hydrogel technology. As part o...
Shareholder Meetings
NexGel Inc Cancels Special Stockholder Meeting
Neutral
Nov 24, 2025
On November 21, 2025, NexGel Inc.’s Board of Directors decided to cancel a Special Meeting of Stockholders that was scheduled for November 26, 2025. The meeting was initially intended to vote on a proposal to significantly increase the compa...
Business Operations and StrategyFinancial Disclosures
NexGel Inc Reports Q3 2025 Financial Results
Neutral
Nov 12, 2025
On November 11, 2025, NEXGEL, Inc. reported its third quarter 2025 financial results, showing a slight decrease in net revenue to $2.93 million compared to the previous year. Despite a flat revenue, the company improved its gross profit margin to ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.